AzTrials
AzTrials

Tobacco DependenceNCT06952725

Chatbot for Online Support Groups to Treat Tobacco Addiction

A study testing online quit-smoking support group with intelligent chatbot and online quit-smoking support group with unintelligent bot in people with Tobacco Dependence and Tobacco Use Disorder, run by University of California, Irvine.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Investigators will conduct a pilot RCT to test the efficacy of an intelligent chatbot to aid small, private, quit-smoking peer support groups. Participants will be randomized to an intervention arm (chatbot-enhanced support group), or a control arm (support group only). Read more about this study

Who is it for?
Ages 18 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Tobacco Dependence, Tobacco Use Disorder
What is being tested?
online quit-smoking support group with intelligent chatbot and online quit-smoking support group with unintelligent bot
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
No sites listed yet
Study dates
1 Dec 2026to 1 Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Cigarette smokers (can also use e-cigarettes)
  • Ages 18-75 years
  • English speaking
  • Smart phone with unlimited data
  • 100 cigarettes lifetime
  • Prepared to quit smoking within 10 days of study start
Show all 11Show fewer
  • Active text and email
  • Use of social media or group messaging
  • Home address provided
  • Contact information for a collateral provided
  • Setup of a GroupMe account for study

Who cannot join

  • No NRT health contraindications
  • 5+ cigarettes per day
  • Not an illicit drug user
  • Not a daily marijuana/cannabis user

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Cornelia A Pechmann, PhD contact

3108920619

cpechman@uci.edu

Ian G. Harris, PhD contact

9498248842

harris@ics.uci.edu

About this study

Official title: Intelligent Chatbot for Online Support Groups to Treat Tobacco Addiction

Investigators will conduct a pilot RCT to test the efficacy of an intelligent chatbot to aid small, private, quit-smoking peer support groups. Participants will be randomized to an intervention arm (chatbot-enhanced support group), or a control arm (support group only). In the intervention arm (N=60), each support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). The intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so. In the control arm (N=60), the support groups will be connected to an automated message-posting bot running on a secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot. But both the intelligent chatbot and the automated message-posting bot will post a pre-written daily discussion topic to encourage participants to discuss issues known to facilitate tobacco cessation or group bonding.

Read the detailed description

Investigators will conduct a pilot RCT to test the efficacy of an intelligent chatbot to aid small, private, quit-smoking peer support groups. For this pilot RCT, investigators will use a 2-armed parallel group trial design with an active treatment concurrent control. Participants will be randomized to the intervention arm (chatbot-enhanced support group), or the control arm (support group only). All groups will run on GroupMe, a free group chat platform. Investigators will recruit cohorts of 30 smokers, in 4 waves (N=120). After recruitment is complete, a statistician will randomly assign 15 participants to the intervention arm and 15 participants to the control arm. Investigators will place 15 people in each support group arm to ensure a critical mass even with the expected participant attrition. After randomization, each participant will stay in their assigned arm for study duration. Prior to study start, each participant will receive 8 weeks of combination NRT, including nicotine patch and gum or lozenges (their choice), consistent with clinical practice guidelines for tobacco cessation. In the intervention arm (N=60), each support group will be connected to the intelligent chatbot running on a secure local server as a trained LLM (large language model). This chatbot will monitor all posts in the group and seek to comprehend these posts using the training it has been provided. If a group member makes a post and no one responds with about 10 seconds, the chatbot will respond using one of its 25 response libraries created from knowledge bases, which contain over 1k responses in total. In effect, the intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so. Furthermore, every day at 5 PM Pacific, 8 PM Eastern, the chatbot will post a pre-written daily discussion topic, to encourage participants to discuss issues known to facilitate tobacco cessation or group bonding. In the control arm (N=60), the support groups will be connected to an automated message-posting bot running on a secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot; it will not respond to posts if no human group member does but, instead, remain silent. However, it will post the same daily discussion topic, and at the same time of day, as the intelligent chatbot. Each night, investigators will download each group's past 24-hour posts. These downloads will show each post verbatim along with the datetime stamp and poster username (including posts by the chatbot and automated message-posting bot). Using these downloaded posts, investigators will measure the primary outcome: the total number of posts made by each human participant, excluding the chatbot or bot. In addition, investigators will measure participants' bio-confirmed smoking abstinence and their NRT usage at 1-month and at 3-month intervention end. Trained research staff who are blind to study arm will contact participants via email, text and phone. They will ask participants the following 4 questions: Over the past 7 days, how many cigarettes have they smoked? Over the past 7 days, how many times have they vaped or use e-cigarettes with nicotine? Over the past 7 days, how many times have they used tobacco products other than cigarettes, e.g., cigars, pipe, snuff, chew, snus, or hookah? Over the past 7 days, how many times have they used Nicotine Replacement Therapy or NRT, e.g., patches, gum or lozenges? At 3-month intervention end, investigators will seek to bioconfirm self-reported smoking abstinence. If a participant reports no use of tobacco and no NRT use over the past 7 days, or refuses to answer, investigators will mail out a cotinine saliva test and set up a video (e.g., zoom or FaceTime) appointment at a convenient time for them to take it. Each participant's saliva test will be observed by trained research staff blind to study arm. If a participant recently used NRT, the saliva test will pick up that NRT, and so the test will not be a valid indicator of their smoking status. Therefore, investigators will not give a saliva test current NRT users and instead record them as NRT users. Investigators will incentivize participants to take the saliva test with gift cards.

Being tested
online quit-smoking support group with intelligent chatbot, online quit-smoking support group with unintelligent bot
Keywords
tobacco use addiction, online support group, chatbot
Medical subject headings
Tobacco Use Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • online quit-smoking support group with intelligent chatbotBehavioural

    In the intervention arm (N=60), each quit-smoking peer support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). This chatbot will monitor all posts in the group and seek to comprehend these posts using the training it has been provided. If a group member makes a post and no one responds with about 10 seconds, the chatbot will respond using one of its 25 response libraries created from knowledge bases, which contain over 1k responses in total. In effect, the intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so.

  • online quit-smoking support group with unintelligent botBehavioural

    In the control arm (N=60), the support groups will be connected to our original automated message-posting bot running on our secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot; it will not respond to posts if no human group member does but, instead, remain silent. However, it will post the same daily discussion topic, and at the same time of day, as the intelligent chatbot.

Study groups in NCT06952725
Study groupRoleWhat they receive
test: support group with intelligent chatbotExperimentalWhen participants post to their support groups, the intelligent chatbot will detect relevant post types and generate responses which will be posted back to them and their group, if no human responds to the post within about 10 seconds. The intelligent chatbot will also post a daily discussion topic.
Receives: Behavioral: online quit-smoking support group with intelligent chatbot
control: support group with unintelligent botActive comparatorThe unintelligent chatbot will not respond to participants' posts; it will merely post a daily discussion topic.
Receives: Behavioral: online quit-smoking support group with unintelligent bot

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall posts per participant

    Each night, our study website will download each group's past 24-hour posts in both the test and control conditions labeled by date and poster.

    Measured: End of 90-day intervention

Secondary outcomes (3)
  1. Bio-confirmed smoking abstinence

    We will measure smoking abstinence at 90-day intervention end, bioconfirmed with a saliva test, to conduct a power analysis for a larger RCT.

    Measured: End of 90-day intervention

  2. NRT use at 1-month

    In a survey (using email, text or phone), 30 days after intervention start, we will measure past 7-day use of Nicotine Replacement Therapy or NRT, for descriptive purposes, e.g. to ensure no adverse effects on NRT use.

    Measured: 30 days after intervention start

  3. nrt use at intervention end

    In a survey (using email, text or phone) at the end of the 90-day intervention, we will measure past 7-day use of Nicotine Replacement Therapy or NRT, for descriptive purposes, e.g. to ensure no adverse effects on NRT use.

    Measured: End of 90-day intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2025
  2. Study start1 Dec 2026 (estimated)
  3. Primary completion1 Jun 2028 (estimated)
  4. Study completion1 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06952725
Sponsor's protocol ID
919
Status last verified
May 2026
First submitted
23 Apr 2025
Last updated
22 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Giyahchi T, Singh S, Harris I, Pechmann C. Customized training of pretrained language models to detect post intents in online health support groups. In: Shaban-Nejad A, Michalowski M, Bianco S, eds. Multimodal AI in Healthcare Studies in Computational Intelligence. Springer Nature; 2023:59-76:chap 14.

  • Prochaska JJ, Vogel EA, Chieng A, Kendra M, Baiocchi M, Pajarito S, Robinson A. A Therapeutic Relational Agent for Reducing Problematic Substance Use (Woebot): Development and Usability Study. J Med Internet Res. 2021 Mar 23;23(3):e24850. doi: 10.2196/24850.

    PubMed 33755028
  • Phillips C, Pechmann C, Calder D, Prochaska JJ. Understanding Hesitation to Use Nicotine Replacement Therapy: A Content Analysis of Posts in Online Tobacco-Cessation Support Groups. Am J Health Promot. 2023 Jan;37(1):30-38. doi: 10.1177/08901171221113835. Epub 2022 Jul 11.

    PubMed 35817548
  • Pechmann CC, Yoon KE, Trapido D, Prochaska JJ. Perceived Costs versus Actual Benefits of Demographic Self-Disclosure in Online Support Groups. J Consum Psychol. 2021 Jul;31(3):450-477. doi: 10.1002/jcpy.1200. Epub 2020 Oct 19.

    PubMed 36276230
  • Pechmann C, Pan L, Delucchi K, Lakon CM, Prochaska JJ. Development of a Twitter-based intervention for smoking cessation that encourages high-quality social media interactions via automessages. J Med Internet Res. 2015 Feb 23;17(2):e50. doi: 10.2196/jmir.3772.

    PubMed 25707037
  • Pechmann C, Delucchi K, Lakon CM, Prochaska JJ. Randomised controlled trial evaluation of Tweet2Quit: a social network quit-smoking intervention. Tob Control. 2017 Mar;26(2):188-194. doi: 10.1136/tobaccocontrol-2015-052768. Epub 2016 Feb 29.

    PubMed 26928205
  • Lakon CM, Pechmann C, Wang C, Pan L, Delucchi K, Prochaska JJ. Mapping Engagement in Twitter-Based Support Networks for Adult Smoking Cessation. Am J Public Health. 2016 Aug;106(8):1374-80. doi: 10.2105/AJPH.2016.303256. Epub 2016 Jun 16.

    PubMed 27310342
  • Esmaeeli A, Pechmann CC, Prochaska JJ. Buddies as In-Group Influencers in Online Support Groups: A Social Network Analysis of Processes and Outcomes. J Interact Market. 2022 May;57(2):198-211. doi: 10.1177/10949968221076144. Epub 2022 Apr 26.

    PubMed 35656556

Questions about this trial

What is this clinical trial studying?

A study testing online quit-smoking support group with intelligent chatbot and online quit-smoking support group with unintelligent bot in people with Tobacco Dependence and Tobacco Use Disorder, run by University of California, Irvine.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Cornelia A Pechmann, PhD (3108920619, cpechman@uci.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall posts per participant (time frame: End of 90-day intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06952725, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in